John Simmons, MD
General Practice · Geneva, ALNPI 1922045905
Payments from drug & device makers
Across 163 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$598
- Lilly USA, LLC$424
- Novo Nordisk$233
- Avanir Pharmaceuticals, Inc.$219
- Johnson & Johnson$180
- AstraZeneca$149
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,100100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $598 |
| Lilly USA, LLC | 19 | $424 |
| Novo Nordisk | 10 | $233 |
| Avanir Pharmaceuticals, Inc. | 16 | $219 |
| Johnson & Johnson | 9 | $180 |
| AstraZeneca | 9 | $149 |
| Otsuka America Pharmaceutical, Inc. | 6 | $118 |
| Boehringer Ingelheim | 6 | $113 |
| Novartis | 6 | $105 |
| Shockwave Medical, Inc | 1 | $99 |
| Medtronic | 2 | $98 |
| Idorsia Pharmaceuticals US Inc | 1 | $93 |
| Pfizer | 5 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $76 |
| Amgen | 4 | $62 |
| Eisai Inc. | 4 | $56 |
| Merck | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| GSK | 3 | $49 |
| Evoke Pharma, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Exact Sciences | 2 | $29 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Bioventus LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Athena Bioscience, LLC | 1 | $9 |
How this compares
$3,105 in reported general payments places this provider in the 90th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 169 | $155,724 |
| MounjaroTirzepatide | 145 | $151,157 |
| OzempicSemaglutide | 134 | $141,059 |
| EliquisApixaban | 132 | $116,393 |
| JanuviaSitagliptin Phosphate | 98 | $95,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $74,305 |
| XareltoRivaroxaban | 62 | $71,318 |
| JardianceEmpagliflozin | 51 | $55,425 |
| TrulicityDulaglutide | 33 | $52,305 |
| MyrbetriqMirabegron | 66 | $51,118 |
| EntrestoSacubitril/Valsartan | 36 | $38,395 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $32,047 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $17,212 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $17,089 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $16,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $424 | $203,462178 claims |
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere | $149 | $180,706207 claims |
| Novo NordiskOzempic, Levemir | $233 | $147,764164 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $49 | $123,564155 claims |
| PfizerEliquis, Premarin | $91 | $122,945143 claims |
| MerckJanuvia | $51 | $95,31798 claims |
| Boehringer IngelheimJardiance, Tradjenta | $113 | $71,37672 claims |
| Johnson & JohnsonXarelto | $180 | $71,31862 claims |
| NovartisEntresto | $105 | $38,39536 claims |
| AbbVieCreon, Linzess | $598 | $26,99232 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $93 | $12,31533 claims |
| Sanofi-aventis U.S. LLCMultaq | $38 | $10,05712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,114 general practice providers in Alabama.
Other general practice in Geneva
- Glenn HarnettHoover$4.5M
- Herrera DaniloMobile$716K
- John BurgessBirmingham$212K
- Frank TombrelloBirmingham$163K
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- Scott BoswellJasper$111K
- Gregory FunkGulf Shores$42K
- Toni NeumeierBirmingham$35K
- Alan ColemanAthens$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.